- Imugene (IMU) receives notice of grant from the Japanese Patent Office for its HER-Vaxx immunotherapy
- The patent is titled ‘A vaccine Composition and Uses Thereof’ and protects the method of use and composition of Imugene’s immunotherapy until 2036
- HER-Vaxx is designed to treat tumours that over-express the HER-2/neu receptor such as gastric, ovarian, lung and breast
- Roughly 75 per cent of all gastric cancer diagnoses are in Asia with Japan having the third highest incidence rate of gastric cancer worldwide
- Shares in Imugene are up 5.49 per cent and are trading at 48 cents at 10:45 am AEST
Imugene (IMU) has received notice of grant from the Japanese Patent Office for its HER-Vaxx immunotherapy.
The patent is titled ‘A vaccine Composition and Uses Thereof’ and protects the method of composition and method of use of Imugene’s HER-Vaxx immunotherapy until 2036.
The HER-Vaxx immunotherapy is designed to treat tumours that over-express the HER-2/neu receptor such as lung, breast, gastric, ovarian and pancreatic cancers.
Roughly 75 per cent of all gastric cancer diagnoses are in Asia with Japan having the third highest incidence rate of gastric cancer worldwide.
CEO and Managing Director Leslie Chong commented on the granting.
“Attaining the key Japanese patent is an important milestone,” Ms Chong said.
“This adds extra value to Imugene’s portfolio of B-cell immunotherapies and this will protect them in one of the world’s largest HER2 positive gastric cancer markets until 2036.”
Shares in Imugene were up 5.49 per cent and were trading at 48 cents at 10:45 am AEST.